ClinicalTrials.Veeva

Menu

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Boehringer Ingelheim logo

Boehringer Ingelheim

Status and phase

Completed
Phase 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Treatments

Drug: BI 836826
Drug: Ibrutinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT02759016
1270.15

Details and patient eligibility

About

Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, and who are eligible for treatment with ibrutinib. Objectives of the trial are to determine the recommended Phase 2 dose of BI 836826, and to document the safety and tolerability of BI 836826 when given in combination with ibrutinib

Enrollment

7 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of Chronic Lymphocytic Leukemia (CLL) established according to International Workshop Chronic Lymphocytic Leukemia (IWCLL) criteria.
  • Relapsed or refractory CLL pre-treated with at least one prior line of systemic therapy for CLL.
  • Indication for treatment consistent with IWCLL criteria, i.e. at least one of the following criteria should be met
  • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia.
  • Massive or progressive or symptomatic splenomegaly.
  • Massive nodes or progressive or symptomatic lymphadenopathy.
  • Progressive lymphocytosis in the absence of infection, with an increase in blood Absolute Lymphocyte Count (ALC) >=50% over a 2-month period, or a lymphocyte doubling time (LDT) of <6 months (as long as initial ALC was >=30000/µl).
  • Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy.
  • Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs:
  • unintentional weight loss of 10% or more within the previous 6 months
  • significant fatigue
  • fevers higher than 100.5°F or 38.0°C for >=2 weeks without other evidence of infection
  • night sweats for > 1 month without evidence of infection
  • Clinically quantifiable disease burden defined as at least one of the following:
  • either ALC >10 000/µL, or
  • measurable lymphadenopathy
  • quantifiable bone marrow infiltration documented in a bone marrow biopsy during screening
  • Resolution of all clinically relevant acute non-hematologic toxic effects of any prior antitumor therapy resolved to Grade <=1
  • Baseline laboratory data as defined as:

Hemoglobin (Hb): >=8g/dL Absolute Neutrophil Count (ANC): >=1000/µL Platelet (PLT): >=25000/µL Glomerular Filtration Rate (GFR) or Creatinine Clearance: >=30ml/min Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT): <3 x Upper Limit of Normal (ULN) Bilirubin - total: <1.5 x ULN Activated Partial Thromboplastin Time (aPTT), Prothrombin Time (PT) or International Normalized Ratio (INR): <=1.5 x ULN PT <=1.5 x ULN, INR <=1.5

  • Male or female patients. Women of childbearing potential must agree to use highly effective methods of birth control during the trial and for at least 1 year after the last dose of BI 836826 and 1 month after the last dose of ibrutinib.
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.
  • Age 18 years and older
  • Eligible and able to secure sourcing for ibrutinib
  • Written Informed Consent
  • Further Inclusion criteria apply

Exclusion criteria

  • Known transformation of Chronic Lymphocytic Leukemia (CLL) to an aggressive B-cell malignancy at the time of screening
  • Prior allogeneic stem cell transplant within one year or active graft vs. host disease.
  • History of a non-CLL malignancy except for adequately treated in situ, stage 1 or 2 carcinoma in Complete Response (CR), or any other cancer that has been in CR for >=2 years after end of cancer treatment.
  • Active, uncontrolled autoimmune cytopenia. Patients with autoimmune cytopenia which is controlled with corticosteroids at doses of <=20 mg prednisolone or equivalent may be enrolled.
  • Previous CLL treatment with a CD37-targeting antibody or a CD37-antibody drug conjugate.
  • Previous treatment with ibrutinib
  • Previous treatment with another Bruton's Tyrosine Kinase (BTK) -inhibitor.
  • Ongoing systemic immunosuppressive therapy other than corticosteroids.
  • Active bacterial, viral, or fungal infection requiring systemic treatment at the time of study entry.
  • Human Immunodeficiency Virus (HIV) infection
  • Active hepatitis B or C as evidenced by detection of virus specific Deoxyribonucleic Acid (DNA) or Ribonucleic Acid (RNA).
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment
  • Chronic persistent atrial flutter or atrial fibrillation. Patients with intermittent atrial fibrillation may be enrolled if without episode for >= 6 months and without indication for anti-coagulation
  • Requirement for chronic anticoagulation with warfarin or with direct oral anticoagulants at the time of screening.
  • Chronic treatment (i.e. >7 days) with a strong Cytochrome P450 (CYP3A) inhibitor which cannot be terminated prior to the first dose of ibrutinib.
  • Unstable angina pectoris, uncontrolled hypertension, uncontrolled asthma or other pulmonary disease
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Further Exclusion criteria apply

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

7 participants in 1 patient group

BI 836826
Experimental group
Description:
BI 836826 administered in combination with Standard of Care Ibrutinib
Treatment:
Drug: BI 836826
Drug: Ibrutinib

Trial documents
2

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems